Genelux
completed phase tested primed heavily patients with platinum resistant or platinum refractory ovarian cancer published in jama oncology link | Genelux
Company
Deck Type
Sector
Industry
Deck date
February 2024
Slide
10 of 37
Similar slides by Genelux
See diffirences between slides (animation)
Investor Presentation
December 2023
completed phase tested primed heavily patients with platinum resistant or platinum refractory ovarian cancer published in jama oncology link | Genelux
Investor Presentation
October 2023
completed phase tested primed in heavily patients with platinum resistant or platinum refractory ovarian cancer published in jama oncology link | Genelux
Investor Presentation
July 2023
completed phase tested published in jama oncology link | Genelux
Related slides by other companies
Boundless Bio
IPO
March 2024
spyglass reveals cancer targets both novel and validated that intersect distinct nodes of | Boundless Bio
RenovoRx
IPO
August 2021
designed for success expect one phase trial will lead to approval and commercial adoption | RenovoRx
Erasca
Investor Presentation
August 2023
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
Theravance Biopharma
Results
May 2023
progress against targets | Theravance Biopharma
Other recent decks by Genelux
See all presentations (4 decks)
Investor Presentation
December 2023
Investor Presentation
October 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io